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Licensing and decisions on public health use of a vaccine rely on a robust clinical development 
program that permits a risk-benefit assessment of the product in the target population. Studies 
undertaken early in clinical development, as well as well-designed pivotal trials, allow for this 
robust characterization. In 2012, WHO published guidelines on the quality, safety and efficacy of 
live attenuated dengue tetravalent vaccines. Subsequently, efficacy and longer-term follow-up data 
have become available from two Phase 3 trials of a dengue vaccine, conducted in parallel, and the 
vaccine was licensed in December, 2015. The findings and interpretation of the results from these 
trials released both before and after licensure have highlighted key complexities for tetravalent 
dengue vaccines, including concerns vaccination could increase the incidence of dengue disease in 
certain subpopulations. This report summarizes clinical and regulatory points for consideration 
that may guide vaccine developers on some aspects of trial design and facilitate regulatory review 
to enable broader public health recommendations for second-generation dengue vaccines.
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Introduction
The first dengue vaccine (CYD-TDV or Dengvaxia®, by Sanofi Pasteur) was licensed in 
December 2015, after decades of research and clinical development. Despite a significant 
global demand, dengue vaccine development has been difficult for several reasons, including 
the need for a tetravalent vaccine with efficacy against each of the four dengue virus 
(DENV) serotypes, the lack of representative animal models, and concerns about vaccine-
induced immune enhancement as seen in natural infection [1,2]. While the successful 
registration of the first dengue vaccine represented a major milestone, there have also been 
setbacks. First, the results of the multi-center pivotal Phase 3 trials highlighted important 
limitations [3,4]. In these trials, in which three vaccine doses were given separated by six 
months, efficacy varied according to serotype, age and baseline dengue serostatus. Because a 
safety signal was observed in young children in one of the trials during longer-term follow-
up, children below 9 years of age were subsequently excluded from the age-indication of 
this vaccine. In April 2016, the World Health Organization (WHO) recommended countries 
consider introducing the first licensed dengue vaccine only in settings with a high burden of 
dengue disease, for the age group of 9–45 years, with seroprevalence criteria in the target 
age group for vaccination of ideally >70% [5]. WHO issued this recommendation due to 
limited evidence supporting the efficacy, safety, and long-term performance of the vaccine in 
DENV-seronegative individuals age >9 years, concerns about an excess risk of hospitalized 
dengue in younger (2–5 years old) subpopulations, and lower efficacy in DENV-seronegative 
subpopulations included in the current license [6]. WHO and advisors called on the 
company to further interrogate the clinical trial data and conduct additional targeted studies 
to further analyze the issue of safety and risk for increased incidence of symptomatic 
infection among vaccinated seronegative persons, to be done as soon as possible [5–7]. A 
proposal for the necessary post-licensure studies to address the question of safety in 
seronegatives, including study designs, has been published [8].
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On November 29, 2017, Sanofi Pasteur announced that it had used a new NS1 assay on sera 
taken after the 3rd dose and imputation methods in order to classify participants 
retrospectively into those likely to have been seronegative or seropositive at the time of the 
first vaccine dose. These results were used to estimate the long-term safety and efficacy of 
the vaccine by serostatus prior to vaccination [9]. The company found an increased risk of 
severe and hospitalized dengue associated with vaccination among seronegatives. The 
company has stated its intention to change the label so that individuals who have not been 
previously infected by dengue virus should not be vaccinated. The WHO Global Advisory 
Committee on Vaccine Safety and the WHO Secretariat published interim statements on 
December 7, 2017 [10], and December 22, 2017 [11], respectively. A full evidence review is 
now underway to revise the WHO position.
In 2012, WHO issued guidelines on the regulation of dengue vaccines, including their 
clinical development [12]. In light of the experience of clinical development and of trying to 
formulate evidence-based policy-making for the first licensed dengue vaccine, WHO 
convened a group of independent experts on March 21, 2017, to develop points for 
consideration for the clinical evaluation of second-generation dengue vaccines. Here we 
summarize the discussions and recommendations from this ad hoc consultation, which took 
place before the Sanofi Pasteur announcement, but the points for consideration are all the 
more relevant in light of the new information. These reflections may help vaccine 
developers, regulators and public health decision-makers in planning studies or evaluating 
data on dengue vaccines. It does not replace original WHO guidance [12], but provides 
additional perspectives.
Findings from the trials of the first-generation dengue vaccine
The first licensed dengue vaccine, CYD-TDV or Dengvaxia®, is a recombinant live 
attenuated, tetravalent dengue vaccine based on the yellow fever 17D vaccine backbone. The 
structural genes (prM-E) of the YF17D virus vector are replaced by the structural genes of 
each the four DENV serotypes. The initial license was typically with an indication for 
individuals aged 9–45 years living in endemic areas. Licensure was based on two large 
multicenter Phase 3 trials conducted in Asia and Latin America with over 30,000 trial 
participants; serostatus at baseline and immune responses before and after vaccination were 
assessed in a subset of about 2,000 subjects in each trial [3,4,13]. A post-hoc analysis of 
stratifying vaccine efficacy and safety by <9 and ≥9 years of age across all trials led to the 
age indication starting at 9 years of age even though two of the pivotal trials enrolled down 
to 2 or 4 years of age. CYD-TDV is now registered in 19 countries [14].
There were several unexpected findings in the trials that challenged previously held ideas 
about how this vaccine protects and the groups in whom protection might be greatest, and 
raised concerns of late onset vaccine-associated enhanced disease, which were later 
corroborated by the company’s new analysis.
1) Balanced immunogenicity between dengue serotypes, defined as a geometric mean 
neutralizing antibody titer (GMT) as measured by standard plaque reduction neutralization 
test (PRNT), did not correlate with serotype-specific efficacy. In the Phase 3 trial in Asia, 
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GMT measured 28 days after the third vaccine dose were 166, 355, 207, and 151 against 
DENV1, DENV2, DENV3, and DENV4, respectively; however, the respective vaccine 
efficacies were 54.5%, 34.7%, 65.2%, and 72.4% [3]. The highest GMT was raised against 
DENV2, while for this serotype the vaccine efficacy was the lowest; the reverse relationship 
was seen for DENV4. Similar trends were seen in the Phase 3 trial in Latin America [4]. A 
formal analysis of the relationship between the level of neutralizing antibody at day 28 after 
the final vaccine dose and subsequent risk of disease in the 13–25 months after the first dose 
has been published. While higher neutralizing antibodies were shown to be associated with a 
reduced risk of disease, there was no threshold by which protection by CYD-TDV could be 
reliably predicted [15].
2) Vaccine efficacy varied significantly by prior DENV infection status [3,4]. In a post-hoc, 
pooled analysis of the two Phase 3 trials, vaccine efficacy was 78.2% (95%CI 65.4%, 
86.3%) in trial participants who were DENV-seropositive at baseline (hereafter referred to as 
“seropositive”), and 38.1% (95%CI −3.4%, 62.9%) in trial participants who were DENV-
seronegative at baseline (hereafter referred to “seronegative”). In participants 9–16 years of 
age, vaccine efficacy in seronegatives was 52.5% (95%CI 5.9%, 76.1%).
3) In the third year of follow-up (12–24 month after the last vaccine dose), participants aged 
2–5 years in the Phase 3 trial in Asia had an increased risk of hospitalized dengue, compared 
to the placebo group, with a relative risk (RR) 7.5 (95%CI 1.2, 313.8) [7,13]. Overall, the 
RR of hospitalized dengue during the study based on data available as of October, 2015, was 
1.3 in the 2–5 year-old age group (95%CI 0.8, 2.1). The reason for this elevated risk in the 
2–5 year age-group was incompletely understood at the time of licensure. One hypothesis 
proposed is that in seronegative individuals, the vaccine acts like an asymptomatic primary 
infection, priming vaccinees to experience a “secondary-like” clinical presentation upon a 
first natural exposure to DENV [16–18]. While a DENV infection with a given serotype is 
thought to provide lifelong protection against a second infection with that serotype, second 
wildtype DENV infections of a different serotype than the first are associated with more 
severe clinical outcomes [19]. Serostatus was correlated with age in the Phase 3 trials: in 
Asia, the proportion of participants who were seropositive at the time of first vaccination 
was 51% for 2–5 year-olds, 72% among 6–11 year-olds and 81% among 12–16 year-olds 
[3]. The findings of the additional analyses announced in late November 2017 revealed that 
the increased relative risk for more severe disease was independent of age. The analysis 
confirmed that CYD-TDV provided persistent protective benefit against severe dengue 
among seropositives, but for seronegatives, the analysis found that in the longer term there 
was about two times higher risk of more severe dengue and hospitalizations in vaccinated 
participants [9,10].
4) Follow-up analyses in a limited number of seronegative vaccinees suggest type-specific 
neutralizing responses were limited mainly to DENV4 [20]. This finding suggests that the 
protection of seronegative subjects observed against DENV1, DENV2, and DENV3 may 
have resulted predominantly from heterotypic cross-protection, rather than type-specific 
monotypic protection. If the heterotypic cross-protection induced by vaccination is 
temporary, it may support the biologic mechanism for the increased risk seen initially in the 
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2–5 year-olds, the age group that had the highest proportion of seronegatives, and 
subsequently in seronegative participants of any age.
5) It was also expected that the highest protection would be seen after subjects had received 
the full 3 doses of vaccine (“per protocol” analyses), but vaccine efficacy was found to be 
similar for “intention to treat” analyses that included all cases occurring after the first dose 
[3,4]. Whether this has implications for the ability of this or other live vaccines to boost the 
immune response at a later stage is currently unknown.
The first dengue vaccine has significant limitations in relation to large-scale public health 
use. An ideal dengue vaccine would offer high protection against clinical disease due to any 
serotype and would be similarly efficacious and safe regardless of prior DENV infection and 
age at vaccination. Protection would ideally be long-lasting, and vaccine-boosting of 
immunity should be possible if protection wanes over time. Additional dengue vaccine 
candidates are currently in advanced clinical development, and regulators and policy makers 
will want to ascertain whether or not second-generation candidates share similarities to 
CYD-TDV. Below we outline some considerations that may help with trial design and 
interpretation of clinical trial results, as well as in licensing and use decisions. Several of the 
considerations have already been integrated into ongoing dengue clinical development 
programs.
Learning from natural DENV infection
Tetravalent vaccination, representing simultaneous exposure to the four DENV antigens, is 
fundamentally different from sequential exposure to individual DENV serotypes through 
natural infection. Nevertheless, it is important to consider aspects of live viral vaccines 
through the lens of what is known about natural infection. Firstly, the DENV serotypes are 
four genetically and serologically distinct viruses [21]. A tetravalent vaccine, therefore, 
combines four live vaccines, with risk of interference between the components. Many years 
have been spent in early phases of live dengue vaccine development attempting to find the 
right formulation to overcome such interference [21].
Humoral immunity induced by infection with a dengue virus has been characterized as 
homotypic against the infecting serotype and heterotypic against the non-infecting other 
(and not previously seen) serotypes. While homotypic immunity is long-lasting, heterotypic 
immunity that protects against non-infecting serotypes is transient. It is believed that 
heterotypic immunity induced after a primary wildtype DENV infection lasts about 1–2 
years, after which the individual is predisposed to more severe outcomes associated with a 
second wildtype infection with another serotype [23–25]. However, as 3rd and 4th DENV 
infections with different serotypes are rarely associated with severe disease, and it is 
assumed that heterotypic immunity following a second infection is long-lasting [26]. Thus, it 
is important to distinguish between transient and long-lasting heterotypic (also termed 
“multitypic”[27]) immunity, the latter likely based on broadly cross-neutralizing antibodies 
elicited by post-primary infections. Ideally, a dengue vaccine should elicit long-lasting type-
specific antibodies against each of the four serotypes and/or long-lasting cross-neutralizing 
heterotypic antibodies.
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Preliminary data from cohort studies suggest the neutralization titers necessary for 
protection are higher than 1:10 [28,29], which has been accepted as a correlate of vaccine 
induced protection for other flavivirus vaccines [30]. Thus, immunogenicity requirements 
for a dengue vaccine may be higher than have been estimated for other monovalent 
flavivirus vaccines, with the caveat that variations in laboratory assays inhibit a quantitative 
comparison between titers against different flaviviruses. A further complication is that 
thresholds of protection may vary by serotype and by candidate vaccine formulation. This 
poses a significant challenge to assessing likely efficacy of second-generation dengue 
vaccines based only on immunogenicity, as well as the use of immunogenicity to bridge 
efficacy to populations not evaluated in clinical efficacy trials.
Considerations for early-stage clinical development of live attenuated 
dengue vaccines
Early phase clinical studies can be valuable to provide information that helps to characterize 
potential interference between vaccine viruses, which influences whether vaccine-induced 
immunity is serotype-specific or heterotypic for each serotype. Additional characterization 
of vaccine candidates using different assays and approaches can be highly complementary 
and may aid in de-risking late-stage development, helping to anticipate vaccine efficacy, 
longer-term protection, and safety in the field. None of the studies outlined below need be 
considered on the critical path to licensure but may bring added value in regulatory and 
policy-making assessments.
Neutralization assays
The limitations of existing neutralization assays have been described [29], but there are 
currently no validated alternatives. Neutralization assays using sera collected shortly after 
vaccination cannot distinguish between monotypic (long-lasting, type-specific), transient 
heterotypic, or long-lasting heterotypic (multitypic) antibodies [27]. In addition, they may 
not measure antibodies that may enhance infection. Therefore, any classical measurement of 
neutralizing antibodies must be interpreted in the context of time since exposure to infection 
or vaccination. While repeated measurements over time may offer better characterization of 
a post-vaccination immune response, the level(s) of antibody required for robust protection 
is not yet known. Data from any trial in which both pre-infection serological responses and 
disease outcomes have been measured can be used to help determine which assays should be 
further investigated for determining a correlate of protection.
There may be value in trying to optimize neutralization assays to best reflect the immune 
response elicited by vaccination, such as using Fcy-receptor bearing cells and measuring 
neutralization using a variety of viral strains, including low-passage strains from more recent 
clinical isolates. However, these modifications are still considered exploratory. It is noted 
that non-neutralizing antibodies may also contribute to protection; for instance, dengue NS1 
interacts with the complement system and may directly contribute to the vascular 
permeability syndrome, while antibodies to NS1 can confer protection by blocking its 
pathogenic effects [27,31] .
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Vaccine infectivity and interference
Live attenuated vaccines elicit human immune responses through vaccine viral replication. 
Thus, for a tetravalent vaccine to generate type-specific immune responses to each of the 
four serotypes, it is thought that each of the four vaccine components should replicate within 
the host. Demonstrating replication for each of the four vaccine viruses, even within the 
same individual, when administered as a live tetravalent vaccine, is highly desirable given 
the potential risk of interference.
The ability of vaccine viruses to replicate and the quality of vaccine-induced immunity can 
be measured by multiple means, and such studies are important to perform, at least initially, 
in a flavivirus-naïve study population. Potential options include: 1) recovering and 
quantifying vaccine virus through culture (e.g. [32]); 2) detecting and quantifying viral RNA 
by RT-PCR (e.g. [33]), ideally by detecting negative strand RNA since this indicates viral 
replication, not just presence of vaccine virus; and 3) antibody depletion assays to determine 
whether type-specific responses were generated for each of the four serotypes (e.g. [20]). It 
is acknowledged that there are challenges with assay sensitivity, and recovering and 
quantifying vaccine virus from each of the four serotypes in an individual is a high bar. At a 
minimum, indicating the proportion of a vaccinated group with detectable replication of 
each vaccine virus provides basic characterization, particularly when this is conducted 
serially over 14 days after the first vaccine dose (e.g. [34]). The more evidence generated to 
support type-specific immune responses against the multiple vaccine viruses, the more 
confidence regulators and policy makers may have in their assessment of long-term efficacy 
and public health utility.
Another approach has been to study immunogenicity of each monovalent vaccine separately, 
as well as in combination, and to compare levels of serotype-specific antibody. A problem 
with this approach is the limitations of neutralization tests to measure type-specific long-
lasting protective antibody, especially at time points close to vaccination. Furthermore, viral 
replication kinetics of monovalent candidates may differ when formulated as a tetravalent 
vaccine and it would be important to conduct studies early in development defining these 
kinetics over a broad range of days following vaccination. Longer-lasting antibodies, beyond 
one year, may be more indicative of protection. Additionally, studies in non-human primates, 
especially challenge studies demonstrating protection against viraemia at a meaningful time-
point (e.g., >12 months after the last vaccine dose), are of value, noting limitations in 
extrapolating from the animal model to humans.
Controlled Human Infection Model
Although not required as part of the critical path for vaccine licensure, controlled human 
infection model (CHIM) trials can provide initial proof-of-concept that a vaccine is likely to 
have clinical benefit, and this may de-risk decisions to evaluate candidates in large Phase 3 
efficacy trials. There is also the potential for dengue CHIM to assist in the identification of 
an immune correlate of risk or protection and potentially expand the indication for a vaccine. 
There are currently both attenuated infection models (which do not cause disease) and 
disease models [35]. In all models, the virus is administered parenterally, which potentially 
confounds the interpretation of outcomes, as the induction of infection via mosquito bite 
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extends the incubation period and allows both innate and adaptive immunity to condition the 
course of the infection. The validity of efficacy measured by CHIM has yet to be 
established, but an initial assessment can be made once efficacy results from a Phase 3 trial 
are available for one vaccine candidate that has also been evaluated by CHIM [36,37]. How 
well CHIM efficacy estimates will predict efficacy against wild-type virus may also differ 
between the infection and disease model.
Challenge strains have not yet been developed for all DENV serotypes, which would be 
needed for a comprehensive assessment. CHIM studies with each of the four serotypes 
would incur high costs, and DENV serotypes for which there may be a priori concern about 
interference, such as those with lower seroconversion rates, could be prioritized. 
Additionally, the timing of challenge is critical in the interpretation of results due to the 
potential for short-lived cross-protection. The longest time interval for a dengue CHIM 
between vaccination and challenge is currently 3.5 years [38]. Ideally, volunteers would be 
challenged at 12 months or greater after vaccination, after transient heterotypic immunity 
would be expected to have waned. Otherwise, it is possible that even high efficacy 
demonstrated through CHIM could reflect the presence of transient heterotypic protection.
Considerations for late-stage clinical development
Until a surrogate or correlate of protection is established [30], pivotal efficacy trials of 
dengue vaccines will need to be conducted based on a clinical endpoint. The licensure of the 
first dengue vaccine introduces additional complexities to the design and site selection for 
second-generation vaccine development and will require close consultation with national 
regulatory authorities.
Efficacy trials of dengue vaccines have specified a primary endpoint of virologically-
confirmed dengue of any severity due to any serotype. Even with these broad endpoints, it 
has been necessary to include 10,000–20,000 participants in trials to have statistical power to 
demonstrate vaccine efficacy. Such trials have very high cost and it is important that the 
designs of Phase 3 pivotal trials are optimized based on lessons learned from the first pivotal 
trials.
The objectives of a clinical development program for a dengue vaccine are likely to remain 
largely as outlined in the initial WHO guidelines [12], with the addition of critical analyses 
of immunological and clinical outcomes by pre-vaccination immune status. Thus, the 
clinical evaluation of a candidate live tetravalent dengue vaccine should document 1) the 
immune responses elicited by the vaccine against each of the four DENV serotypes 
according to pre-vaccination immune status; 2) vaccine efficacy for the prevention of 
symptomatic dengue of any severity caused by any DENV serotype over an appropriate 
minimum period of observation (preferentially 5 years) according to pre-vaccination dengue 
immune status; and 3) the safety profile according to pre-vaccination immune status. As 
further outlined in the WHO guideline, preliminary evidence should be gathered showing the 
absence of a significant signal that the immediate and longer-term immune response to a 
candidate dengue vaccine predisposes vaccinated individuals (or a subset) to an increased 
risk of dengue and/or severe dengue disease with subsequent natural infections, relative to 
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the control group. Finally, surrogate markers or immune correlates of protection and/or risk 
should be defined [12].
Immune status at vaccination
It is essential that a pivotal trial be designed so that vaccine efficacy, safety, and duration of 
protection can be assessed by serotype and serostatus. The finding of a substantially 
increased risk of hospitalized dengue associated with vaccination of seronegatives in the 
longer-term following the last dose of the CYD-TDV vaccine [11] has led to increased focus 
on vaccine efficacy and safety in seronegative populations. Biologically this is not 
surprising, as serostatus is a strong modifier of immune responses, infection and disease 
susceptibility, and vaccine take. It is now clear that vaccine efficacy and clinical outcomes 
should always be evaluated stratified by baseline neutralizing antibody to DENV. In some 
cases, it may also be appropriate to consider the influence of prior infection with other 
prevalent flaviviruses [39,40].
It has been proposed, and it is generally accepted, that in future Phase 3 trials of dengue 
vaccines, baseline and post-vaccination blood samples should be collected and sera stored 
from all trial participants, not just a subset [29]. Should testing the entire population at the 
onset be financially and logistically unfeasible, testing a large subset or testing the prior 
stored samples for all cases would provide information on efficacy and safety according to 
prior serostatus. To help characterize the immune response generated by vaccination over 
time, blood samples should be collected at different time points after vaccination, e.g. 
between doses, after the last dose, 6 months after the last dose, 12 months after the last dose, 
and at 12-month intervals for the duration of the trial and follow-up. Additionally, given that 
the role of T cell immunity in vaccine-induced immunity remains unclear, it is desirable to 
also collect PMBCs from as large a subset of participants as possible for exploratory 
analyses.
In order to have sufficient seronegative trial participants to characterize the risk/benefit in 
this subpopulation, the study population could be enriched for seronegative participants, or a 
trial could be powered to demonstrate efficacy in seronegatives. In the two Phase 3 trials of 
CYD-TDV, the incidence of virologically confirmed dengue was similar in unvaccinated 
seronegatives and seropositives (in the Asia trial, incidences of 4.3% (95%CI 2.5–6.6) and 
3.9% (95%CI 2.7–5.4) in seronegatives and seropositives, respectively [3], and in the Latin 
American trial corresponding incidences of 3.2% (95% 1.5–5.9) and 2.3% (1.5–3.5) [4]). 
The seropositive population may have included some individuals who had already 
experienced 2 or more infections at the time of vaccination, a group in which we would 
expect little additional public health value for a vaccine given the low rate of disease 
associated with tertiary and quaternary infections. In the same epidemiological context as 
the Asian trial, 70% efficacy could be demonstrated in seronegatives with as few as ~1200 
trial participants (1-sided alpha=2.5% and 90% power, lower limit of the 95%CI of 0). 
Seronegative study participants could be identified by screening using ELISA, which is less 
costly and labor-intensive than PRNT. While available ELISA kits are not specific enough to 
determine baseline seropositivity given the potential cross-reactivity with other flaviviruses, 
they could be adequate to rule out prior exposure to any flavivirus, including DENV.
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Methods and duration of follow-up
If a live attenuated vaccine stimulates immunity similarly to natural infection, replication of 
only one component in a tetravalent vaccine may demonstrate efficacy against all serotypes 
for the first 1–2 years after the last dose of vaccine [23–25]. Thus, vaccine efficacy estimates 
against each of the four serotypes generated in a 12-month time frame after the last dose 
should be interpreted in the context of potentially transient cross-protection. Twelve months 
post-vaccination is a typical primary endpoint for pivotal trials for other vaccines, but for 
DENV, a longer period of follow-up is needed to establish both safety and the longer-term 
efficacy over multiple dengue seasons, going beyond temporary cross-protection. Hence, 
WHO guidelines recommend subjects to be followed-up for safety and efficacy for at least 
3–5 years from the time of completion of primary vaccination [12]. Registration may be 
sought on the basis of early follow-up data (e.g. 2 years after last dose), but follow-up should 
continue with timely updates provided to regulators throughout their assessment. It is 
important that the same level of surveillance be maintained throughout the duration of the 
study so that changes in vaccine efficacy over time can be detected particularly as any cross-
protection wanes. To maintain the integrity of the trial over this extended timeframe, trial 
participants and investigators who interact with the participants should remain blinded 
unless there is an ethical obligation to inform participants, such as in the post-licensure 
phase when and if there is a national recommendation for vaccination. The method of case 
detection should ideally remain unchanged (i.e., active surveillance) to make meaningful 
comparisons over time. The primary endpoint for vaccine trials has typically been 
virologically-confirmed dengue of any severity as measured by active surveillance in order 
to have a manageable sample size, as hospitalized or severe dengue is relatively rare. 
Capturing both dengue of any severity as well as hospitalized and well-defined severe 
dengue allows for an understanding of whether dengue illness presentation is modified by 
vaccination status, which may vary by time since last vaccination. Clinical data should be 
carefully monitored for any imbalance of symptomatic or severe dengue cases, including in 
subpopulations, and in particular in the period following expected cross-protection.
An extended follow-up period will also allow for additional power to look at secondary 
analyses, such as sustained vaccine efficacy by infecting serotype(s). It is desirable that 
clinical trial sites are chosen such that there is circulation of each of the four serotypes 
within the trial, likely requiring a geographically dispersed multicenter study.
Other regulatory and policy considerations
Registration and public health recommendations would be facilitated by data that indicate 
presence of protective monotypic responses against all vaccine strains, as well as vaccine 
efficacy beyond the period of short-lived heterologous cross-protection, which is likely 
beyond 12 months after the last dose administered. Even if serotype-specific efficacy and 
efficacy in seronegatives are not primary endpoints (as is the case for the two candidates 
currently in Phase 3 trials [37,41]), regulators may require data that provide reassurance that 
the vaccine can be used safely and effectively in the target population. Any public health 
recommendations for use should also take into account such data.
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For some flaviviruses (e.g., Japanese encephalitis), immunobridging has been accepted for 
licensing across vaccine candidates/platforms; however, these vaccines are monovalent 
rather than tetravalent. In the context of dengue vaccines, due to the lack of clear 
understanding of mechanisms of protection and risk, the variability in neutralization assays, 
the lack of assays that properly distinguish various types of neutralizing antibody, and the 
likely differences in elicited immunity by different dengue vaccine candidates, 
immunobridging based on traditional PRNT may be questionable to regulators as the 
primary basis of licensure. Assays able to measure serotype-specific long-lasting protective 
immunity are critically needed. Currently, placebo-controlled efficacy trials are still likely to 
be considered ethical and desirable in many settings. WHO has provided guidance on ethical 
acceptability of placebo-controlled trials in the context of the availability of a licensed 
product [42].
Conclusions
Our understanding of how dengue vaccines can decrease, or increase, the risk of dengue 
disease is evolving. To ensure that regulatory and public health-decision makers can best and 
rapidly utilize the vaccination tools that become available, a robust clinical development 
program is needed that affords adequate characterization of a vaccine candidate’s benefit-
risk profile over a period of time sufficient to predict durable benefit. There are models for 
joint regulatory assessments that may aid national regulatory authorities with complex 
dossiers, and this was done for the first licensed dengue vaccine [43]. Clinical data generated 
in the course of a clinical development program should be made publicly available for 
regulators, policy-makers, and the broader community in a timeframe consistent with 
WHO’s position on clinical trial results reporting [44].
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Points for consideration for the development of second-generation live 
attenuated dengue vaccines
• Early clinical studies are valuable to evaluate the potential for interference 
between individual vaccine viruses and the impact on the development of 
type-specific versus heterotypic immunity.
• Measuring antibody neutralization activity remains the best method of 
defining dengue vaccine immunogenicity; however, current assays do not 
easily distinguish between type-specific antibodies, transient heterotypic 
antibody, and long-lasting heterotypic antibody. Given this uncertainty, the 
critical time point for assessment of immunogenicity as a correlate of durable 
protection should be more than 12 months after the last vaccine dose. Various 
research assays may be complementary.
• Controlled Human Infection Model (CHIM) trials can provide initial proof-
of-concept that a vaccine may have potential for clinical benefit, but greater 
confidence is required in Dengue CHIM performance and challenge should be 
complete 12 months or more after the last vaccine dose.
• For licensure, in the absence of an accepted correlate of protection or risk, 
vaccine efficacy will need to be demonstrated based on clinical outcomes 
collected over a multi-year period (multiple dengue seasons) that support 
durable benefit.
• Pre-vaccination and post-vaccination blood samples should be collected and 
sera stored from all trial participants.
• Dengue serostatus at baseline is a critical variable, and safety and efficacy by 
serostatus should be presented in a stratified analysis.
• Active surveillance used to assess efficacy against all dengue disease and 
severe dengue disease should be in place preferably for at least 3–5 years after 
the last vaccine dose.
• Immunogenicity and efficacy results should be interpreted in the context of 
potential transient heterotypic immunity that could wane over time.
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1. Until a surrogate or correlate of protection or risk is established, efficacy trials 
of dengue vaccines will need to be conducted based on a clinical endpoint.
2. The licensure of the first dengue vaccine and sponsor-requested label revision 
in response to a safety finding introduces additional complexities to the 
design and site selection for second-generation vaccine development and will 
require close consultation with national regulatory authorities.
3. Dengue serostatus at baseline remains a critical variable, and safety and 
efficacy by serostatus should be presented in a stratified analysis.
4. Active surveillance used to assess efficacy against all dengue disease and 
severe dengue disease should be in place for at least 3, and preferably 5, years 
after the last vaccine dose.
5. Immunogenicity and efficacy results should be interpreted in the context of 
potential transient heterotypic immunity that could wane over time.
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